Literature DB >> 19811417

Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia.

Haijing Wu1, Miao Miao, Guangbo Zhang, Yumin Hu, Zhijun Ming, Xueguang Zhang.   

Abstract

Engagement of the membrane program death-1 (PD-1) receptor by its ligands suppresses T cell proliferation and cytokine production. Aberrant over-expression of costimulatory molecules, including PD-1, has been associated with persistent activation of self-reactive T cells in autoimmune diseases. However, the mechanism underlying the dysfunction of PD-1 in the regulation of T-cell activation in such diseases remains unclear. Here, we report the overexpression of CD4(+) and CD8(+) T cell PD-1 and elevated serum levels of soluble PD-1 in aplastic anemia (AA) patients. Detailed characterization of soluble PD-1 revealed that it corresponded to an alternative splice variant PD-1Deltaex3, which lacks the transmembrane domain but has a soluble extracellular domain of the PD-1 molecule. In a further study, PD-1 fusion protein displayed the ability of increasing the proliferation of T cells in vitro, which suggested that soluble PD-1 might serve as an autoimmune antibody to block the function of membrane-bound PD-1 on T cells and lead to aberrant T cell proliferation. Our study revealed a novel pathogenic pathway in which the function of overexpressed PD-1 to restrict over-self-reaction is counteracted by the excessive production of soluble PD-1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811417     DOI: 10.1080/08820130902912332

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  14 in total

Review 1.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

Review 2.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

3.  Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.

Authors:  Kohei Hosokawa; Pawel Muranski; Xingmin Feng; Danielle M Townsley; Baoying Liu; Jared Knickelbein; Keyvan Keyvanfar; Bogdan Dumitriu; Sawa Ito; Sachiko Kajigaya; James G Taylor; Mariana J Kaplan; Robert B Nussenblatt; A John Barrett; John O'Shea; Neal S Young
Journal:  J Immunol       Date:  2016-01-13       Impact factor: 5.422

4.  MEG3 modulates TIGIT expression and CD4 + T cell activation through absorbing miR-23a.

Authors:  Jianhong Wang; Xiangxiang Liu; Caixia Hao; Yingjuan Lu; Xiaohui Duan; Rong Liang; Guangxun Gao; Tao Zhang
Journal:  Mol Cell Biochem       Date:  2018-10-31       Impact factor: 3.396

5.  Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS).

Authors:  Sean F Monaghan; Chun-Shiang Chung; Yaping Chen; Joanne Lomas-Neira; William G Fairbrother; Daithi S Heffernan; William G Cioffi; Alfred Ayala
Journal:  J Transl Med       Date:  2016-11-11       Impact factor: 5.531

6.  Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.

Authors:  Na Li; Zhihua Zhou; Fang Li; Jiao Sang; Qunying Han; Yi Lv; Wenxuan Zhao; Chunyan Li; Zhengwen Liu
Journal:  Oncotarget       Date:  2017-07-11

7.  Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways.

Authors:  Cuiping Liu; Juean Jiang; Li Gao; Xiaoting Wang; Xiaohan Hu; Min Wu; Jian Wu; Ting Xu; Qin Shi; Xueguang Zhang
Journal:  Arthritis Res Ther       Date:  2015-11-25       Impact factor: 5.156

8.  Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.

Authors:  Yanxia Guo; Alice M Walsh; Mary Canavan; Mihir D Wechalekar; Suzanne Cole; Xuefeng Yin; Brittney Scott; Mathew Loza; Carl Orr; Trudy McGarry; Michele Bombardieri; Frances Humby; Susanna M Proudman; Costantino Pitzalis; Malcolm D Smith; Joshua R Friedman; Ian Anderson; Loui Madakamutil; Douglas J Veale; Ursula Fearon; Sunil Nagpal
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

9.  Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis.

Authors:  Stinne R Greisen; Tue W Kragstrup; Jesper Skovhus Thomsen; Aida Solhøj Hansen; Akilan Krishnamurthy; Kim Hørslev-Petersen; Merete Lund Hetland; Kristian Stengaard-Pedersen; Mikkel Østergaard; Lykke Midtbøll Ørnbjerg; Peter Junker; Arlene H Sharpe; Gordon J Freeman; Lakshmanan Annamalai; Malene Hvid; Søren K Moestrup; Ellen-Margrethe Hauge; Anca Irinel Catrina; Bent Deleuran
Journal:  J Transl Autoimmun       Date:  2019-12-18

10.  Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.

Authors:  Jianjun Jin; Jiming Si; Yuanhua Liu; Huanqin Wang; Ran Ni; Jing Wang
Journal:  Respir Res       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.